Item 1.01 - Entry into a Material Definitive Agreement

On September 20, 2022, Acura Pharmaceuticals, Inc. ("we" "Acura" or the "Company"), received a $150,000 loan from John Schutte and to date, we have received a total of $1,675,000. In connection with the $150,000 loan, we issued an unsecured promissory note, or the Schutte Note, in that principal amount to him. The Schutte Note bears interest at 5.25%, and matures on December 31, 2023, at which time all principal and interest is due. Events of default under the Schutte Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full.

The funding provided by Mr. Schutte will be used for operations over the course of the next several weeks. There can be no assurance we will be successful in receiving additional financing. In the absence of the receipt of additional financing by late October 2022, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operation.

The inclusion of a description of the Schutte Note under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Schutte Note is a material agreement not made, or deemed not to be made, in the ordinary course of our business.

Mr. Schutte directly owns approximately 14% of our common stock as of January 30, 2022. Mr. Schutte also controls MainPointe Pharmaceuticals, LLC and is an investor in Abuse Deterrent Pharma, LLC ("AD Pharma"). AD Pharma directly owns approximately 66% of our common stock as of January 30, 2022, which does not include their warrant to purchase 10.0 million shares of the Company's common stock.

Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The contents of Item 1.01 are incorporated herein by reference.





Forward-Looking Statements

Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

Forward-looking statements may include, but are not limited to:

· our ability to fund or obtain funding for our continuing operations, including

the development of our products utilizing our LIMITx and IMPEDE technologies;

· whether we will receive FDA acceptance for an NDA for LTX-03 by the target

date;

· whether our licensees will terminate the license prior to commercialization;

· the expected results of clinical studies relating to LTX-03 or any successor


   product candidate, the date by which such studies will complete and the results
   will be available and whether any product candidate will ultimately receive FDA
   approval;

· the ability of LTX-03 single tablets to achieve bioequivalence or to

demonstrate efficacy in a clinical study;

· whether our licensing partners will develop any additional products and utilize

Acura for such development;

· whether LIMITx will retard the release of opioid active ingredients as dose

levels increase;

· whether the extent to which products formulated with the LIMITx technology

mitigate respiratory depression risk will be determined sufficient by the FDA;

· our and our licensee's ability to successfully launch and commercialize our

products and technologies;

· our and our licensee's ability to obtain necessary regulatory approvals and

commercialize products utilizing our technologies;

· the market acceptance of, timing of commercial launch and competitive

environment for any of our products;

· our ability to develop and enter into additional license agreements for our

product candidates using our technologies;

· the ability to avoid infringement of patents, trademarks and other proprietary


   rights of third parties;




                                       2

· the ability of our patents to protect our products from generic competition and

our ability to protect and enforce our patent rights in any paragraph IV patent

infringement litigation;

· the adequacy of the development program for our product candidates, including

whether additional clinical studies will be required to support an NDA and FDA

approval of our product candidates;

· changes in regulatory requirements;

· adverse safety findings relating to our commercialized products or product

candidates in development;

· whether or when we are able to obtain FDA approval of labeling for our product

candidates for the proposed indications and whether we will be able to promote

the features of our technologies; and

· whether our product candidates will ultimately perform as intended in


   commercial settings.

In some cases, you can identify forward- looking statements by terms such as "may," "will", "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "indicates", "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

Item 9.01 - Financial Statements and Exhibits

Exhibit Number Description


  99.1           Promissory Note of the Registrant dated September 20, 2022
104            Cover Page Interactive Data File (embedded as Inline XBRL document)

© Edgar Online, source Glimpses